Sarepta Therapeutics Inc (SRPT) - Financial and Strategic SWOT Analysis Review

Date: May 9, 2019
Pages: 55
Price:
US$ 125.00
License [?]:
Publisher: GlobalData
Report type: Company Report
Delivery: E-mail Delivery (PDF)
ID: SB14D207594EN
Leaflet:

Download PDF Leaflet

Sarepta Therapeutics Inc (SRPT) - Financial and Strategic SWOT Analysis Review
Sarepta Therapeutics Inc (SRPT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Sarepta Therapeutics Inc (Sarepta) discovers and develops unique RNA-targeted therapeutics, gene therapy and other genetic medicine approaches to treat rare neuromuscular diseases. The company develops drugs based on its proprietary, highly-differentiated and innovative platform technology, phosphorodiamidate morpholino oligomer (PMO) chemistries. Its first commercial product, Exondys 51 is indicated for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping. Sarepta’s key pipeline products using PMO chemistry includes Golodirsen to skip exon 53 of the DMD gene; and Casimersen to skip exon 45 of the DMD gene. Sarepta is headquartered in Cambridge, Massachusetts, the US.

Sarepta Therapeutics Inc Key Recent Developments

Apr 15,2019 Paragon announces its second GMP manufacturing facility and the expansion of its strategic collaboration in manufacturing design and operation with gene therapy leader Sarepta Therapeutics
Feb 28,2019 Sarepta exercises option to acquire Myonexus for $165m
Feb 27,2019 Sarepta Therapeutics Announces Fourth Quarter 2018 and Full-Year 2018 Financial Results and Recent Corporate Developments
Jan 02,2019 Sarepta Therapeutics enters into long-term strategic relationship with Aldevron for GMP-grade plasmid in support of gene therapy development and commercial manufacturing strategy

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

NOTE: Out of security concerns GlobalData requires using corporate email address.
SECTION 1 - ABOUT THE COMPANY

Sarepta Therapeutics Inc - Key Facts
Sarepta Therapeutics Inc - Key Employees
Sarepta Therapeutics Inc - Key Employee Biographies
Sarepta Therapeutics Inc - Major Products and Services
Sarepta Therapeutics Inc - History
Sarepta Therapeutics Inc - Company Statement
Sarepta Therapeutics Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Sarepta Therapeutics Inc - Business Description
Sarepta Therapeutics Inc - Corporate Strategy
Sarepta Therapeutics Inc - SWOT Analysis
SWOT Analysis - Overview
Sarepta Therapeutics Inc - Strengths
Sarepta Therapeutics Inc - Weaknesses
Sarepta Therapeutics Inc - Opportunities
Sarepta Therapeutics Inc - Threats
Sarepta Therapeutics Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Sarepta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Sarepta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Sarepta Therapeutics Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Apr 15, 2019: Paragon announces its second GMP manufacturing facility and the expansion of its strategic collaboration in manufacturing design and operation with gene therapy leader Sarepta Therapeutics
Feb 28, 2019: Sarepta exercises option to acquire Myonexus for $165m
Feb 27, 2019: Sarepta Therapeutics Announces Fourth Quarter 2018 and Full-Year 2018 Financial Results and Recent Corporate Developments
Jan 02, 2019: Sarepta Therapeutics enters into long-term strategic relationship with Aldevron for GMP-grade plasmid in support of gene therapy development and commercial manufacturing strategy
Dec 11, 2018: Sarepta Therapeutics names Mary Ann Gray, Ph.D., to its board of directors
Nov 02, 2018: Sarepta Therapeutics to Present at Credit Suisse 27th Annual Healthcare Conference
Oct 25, 2018: Sarepta Therapeutics announces third quarter 2018 financial results and recent corporate developments
Oct 15, 2018: Sarepta and Lysogene Announce Exclusive License Agreement for LYS-SAF302, a Late-stage Gene Therapy for the Treatment of MPS IIIA, and Grant of Option Rights to an Additional CNS Gene Therapy Candidate
Oct 08, 2018: Sarepta Therapeutics enters into Long-term Strategic Manufacturing Partnership with Paragon Bioservices, greatly enhancing its commercial capacity for Future Gene Therapies
Oct 08, 2018: Sarepta Therapeutics Enters into Long-term Strategic Manufacturing Partnership with Paragon Bioservices

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

Sarepta Therapeutics Inc, Key Facts
Sarepta Therapeutics Inc, Key Employees
Sarepta Therapeutics Inc, Key Employee Biographies
Sarepta Therapeutics Inc, Major Products and Services
Sarepta Therapeutics Inc, History
Sarepta Therapeutics Inc, Subsidiaries
Sarepta Therapeutics Inc, Key Competitors
Sarepta Therapeutics Inc, Ratios based on current share price
Sarepta Therapeutics Inc, Annual Ratios
Sarepta Therapeutics Inc, Annual Ratios (Cont...1)
Sarepta Therapeutics Inc, Interim Ratios
Sarepta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Sarepta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Sarepta Therapeutics Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

LIST OF FIGURES

Sarepta Therapeutics Inc, Performance Chart (2014 - 2018)
Sarepta Therapeutics Inc, Ratio Charts
Sarepta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Sarepta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

COMPANIES MENTIONED

Roche Innovation Center Copenhagen A/S
Alnylam Pharmaceuticals Inc
Pfizer Inc
Ionis Pharmaceuticals Inc
Sanofi
Nippon Shinyaku Co Ltd
Daiichi Sankyo Co Ltd
Skip to top


Ask Your Question

Sarepta Therapeutics Inc (SRPT) - Financial and Strategic SWOT Analysis Review
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: